120 related articles for article (PubMed ID: 7812982)
1. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients.
Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Werner M; Livne PM
Cancer Detect Prev; 1994; 18(5):357-65. PubMed ID: 7812982
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
4. Expression of a 65 kDa oncofetal protein in human prostatic carcinoma.
Hanausek M; Walaszek Z; King TM; Amos CI
Oncol Rep; 2003; 10(5):1387-92. PubMed ID: 12883712
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
7. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
8. [Serum copper and zinc levels in patients with malignant neoplasm of the urogenital tract].
Sanada S; Ogura K; Kiriyama T; Yoshida O
Hinyokika Kiyo; 1985 Aug; 31(8):1299-316. PubMed ID: 4083194
[TBL] [Abstract][Full Text] [Related]
9. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Tedesco M; Arcuri R; Abbolito MR; Casale V; Pericoli MN; Vecchione A; Casciani CU; Greiner JW; Schlom J
Cancer Res; 1996 Nov; 56(22):5293-8. PubMed ID: 8912871
[TBL] [Abstract][Full Text] [Related]
10. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of serum S100ao protein in patients with urogenital diseases and healthy volunteers].
Kikuchi T; Morita T; Hashimoto S; Hara Y; Moriguchi H; Ishikawa S; Kobayashi Y; Ishiyama S; Goto K; Tozuka K
Hinyokika Kiyo; 1990 Oct; 36(10):1117-23. PubMed ID: 2264539
[TBL] [Abstract][Full Text] [Related]
12. Ras p21 onco-protein in the sera of mice carrying an experimentally induced tumor and in human cancer patients.
Kakkanas A; Spandidos DA
In Vivo; 1990; 4(2):115-20. PubMed ID: 2129802
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.
Aderka D; Englemann H; Hornik V; Skornick Y; Levo Y; Wallach D; Kushtai G
Cancer Res; 1991 Oct; 51(20):5602-7. PubMed ID: 1655258
[TBL] [Abstract][Full Text] [Related]
16. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.
Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK
Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811
[TBL] [Abstract][Full Text] [Related]
18. Serum midkine levels are increased in patients with various types of carcinomas.
Ikematsu S; Yano A; Aridome K; Kikuchi M; Kumai H; Nagano H; Okamoto K; Oda M; Sakuma S; Aikou T; Muramatsu H; Kadomatsu K; Muramatsu T
Br J Cancer; 2000 Sep; 83(6):701-6. PubMed ID: 10952771
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of serum soluble tumor necrosis factor receptor-I in patients with head and neck neoplasm].
Dong W; Xu J; Qiao Z; Wang N; Yu R
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):468-70. PubMed ID: 12761967
[TBL] [Abstract][Full Text] [Related]
20. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Suzuki H; Graziano DF; McKolanis J; Finn OJ
Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
